Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Income from Continuing Operations: 2012-2025

Historic Income from Continuing Operations for Agios Pharmaceuticals (AGIO) over the last 14 years, with Sep 2025 value amounting to -$103.4 million.

  • Agios Pharmaceuticals' Income from Continuing Operations fell 110.91% to -$103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$403.0 million, marking a year-over-year decrease of 160.06%. This contributed to the annual value of $673.7 million for FY2024, which is 291.35% up from last year.
  • Agios Pharmaceuticals' Income from Continuing Operations amounted to -$103.4 million in Q3 2025, which was up 8.09% from -$112.5 million recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Income from Continuing Operations peaked at $947.9 million during Q3 2024, and registered a low of -$112.5 million during Q2 2025.
  • Its 3-year average for Income from Continuing Operations is $796,545, with a median of -$91.3 million in 2023.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Income from Continuing Operations spiked by 1,137.97% in 2024, and later plummeted by 110.91% in 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Income from Continuing Operations (Quarterly) stood at -$98.6 million in 2021, then climbed by 5.98% to -$92.7 million in 2022, then decreased by 3.51% to -$95.9 million in 2023, then declined by 0.61% to -$96.5 million in 2024, then tumbled by 110.91% to -$103.4 million in 2025.
  • Its Income from Continuing Operations was -$103.4 million in Q3 2025, compared to -$112.5 million in Q2 2025 and -$90.5 million in Q1 2025.